About
Over 20 years of entrepreneurship in the bio-pharmaceutical and medical device industries, contributed to a unique skillset that is ideal for Dr. Levy's current role, as Tevas CTO, leading the company efforts in identifying, assessing and assimilating new technological solutions.
Prior to joining Teva, Dr. Levy served in a variety of executive roles and as cofounder in innovation-driven, successful biotech and combo device-drug companies. He is a product development expert with a diverse experience and proven track record of success in progressing five different new technologies from an idea to advanced clinical development stages and global commercialization.
Previously he served as VP for R&D at Aposense and at Regentis Biomaterials. Before that, He held the position of VP R&D at ColBar Lifesience that was acquired by J&J on July 2006 and following the acquisition, he served as VP for medical relationships and life cycle management at the consumer division of J&J. Prior to that, he served as CTO of Rostam Ltd. and founded its daughter company, HiGienic Intravaginal Technologies Ltd, which he also headed as CEO. Under his leadership, the company developed the first, FDA approved, tampon drug delivery product which was licensed to Lil' drugs and led to the acquisition of Rostam by Albad. Before Rosatm, Dr. Levy was a co-founder of Gamida-Cell Ltd, where he also held the position of Vice President of R&D and Operations. Earlier, he held senior R&D and regulatory positions at Soreq Radiopharmaceutical, Pharmos Ltd, Mead-Johnson/Bristol-Myers and Teva Pharmaceutics.
Menashe holds a bachelor degree in pharmacy and a Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and completed 3 years Post-doctoral fellowship in the pharmaceutical chemistry department at University of California, San Francisco.
Specialties: Combo drug Device, Drug Delivery Systems, Stem Cell Therapy, Gene Therapy, Bio-Sensors, Bio-electronics.